SCHEMBL22106239

SCHEMBL22106239

CCOC(=O)COc1cc(C)c(CCl)c(C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.45
▸ GLA P06280 1/20 0.45
▸ GAA P10253 3/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ MCL1 Q07820 1/20 0.39
▸ IDH1 O75874 2/20 0.39
▸ ESR1 P03372 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ PPARG P37231 1/20 0.38
▸ PPARA Q07869 1/20 0.38
▸ HPGD P15428 5/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22106241 0.89 KDM4E (0.44) KDM4EGLAGAANPSR1MEN1
SCHEMBL22106146 0.88 KDM4E (0.46) KDM4EGLAGAANPSR1MEN1
SCHEMBL23409414 0.81 GAA (0.44) KDM4EGAANPSR1MEN1KMT2A
SCHEMBL22106274 0.81 KDM4E (0.44) KDM4EGLAGAANPSR1MEN1
SCHEMBL22106070 0.80 GAA (0.43) KDM4EGAANPSR1MEN1KMT2A
SCHEMBL23003777 0.76 GAA (0.48) KDM4EGLAGAANPSR1MEN1
SCHEMBL16571344 0.76 GAA (0.50) KDM4EGLAGAANPSR1MEN1
SCHEMBL22095708 0.76 THRB (0.63) —
SCHEMBL16571563 0.75 KDM4E (0.51) KDM4EGLAGAANPSR1KMT2A
SCHEMBL24133259 0.74 KDM4E (0.45) KDM4EGLAGAANPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827596-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-11-28 — — US disclosed
US-11827596-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-11-28 — — US disclosed
US-11827596-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-11-28 — — US disclosed
CN-113423684-A Novel thyromimetic agents 速通医疗公司 2021-09-21 — — CN disclosed
US-20200361849-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2020-11-19 — — US disclosed
US-20200361849-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2020-11-19 — — US disclosed
WO-2020123861-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2020-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361849-A1 NOVEL THYROMIMETICS TPO, THOP1, TSHR KDM4E 3853/4885GLA 540/4885GAA 1388/4885
US-11827596-B2 Thyromimetics TPO, TSHR, TTR KDM4E 3916/4885GLA 539/4885GAA 1574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback